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A B S T R A C T
Background: Almost half of all cases of invasive aspergillosis (IA) occur in the intensive care unit (ICU), with
mortality rates of 70–80% for probable or proven cases. IA has become a major concern among non-neutropenic
patients in the ICU with chronic obstructive pulmonary disease (COPD) but although prompt, appropriate an-
tifungal therapy is crucial, diagnosis in this situation is challenging. Criteria for a probable diagnosis in critically
ill patients have been proposed to help to expedite therapy.
Methods: A case of probable invasive pulmonary aspergillosis (IPA) in a non-neutropenic patient admitted to the
ICU was used to illustrate potential issues in the diagnostic work-up and management of patients in this setting.
Results: A non-neutropenic 69-year-old man with COPD receiving clomipramine was diagnosed in the ICU with
probable invasive aspergillosis based on the presence of severe chronic obstructive pulmonary disease, suspected
X-linked granulomatous disease, nodular infiltrates and galactogamman positivity on bronchoalveolar lavage
(BAL) fluid. Voriconazole was unsuitable due to the patient's prolonged QT interval and risk of a drug–drug
interaction with clomipramine. Isavuconazole was initiated and the patient's condition improved. The three-
month course of isavuconazole treatment was well-tolerated and resulted in compete recovery of the patient.
Conclusions: Voriconazole is a standard first-line treatment for IA but intravenous therapy is associated with
toxicity and the potential for drug–drug interactions. Isavuconazole is another first-line therapy which was
effective and safe in the management of this critically ill non-neutropenic patient with baseline QT prolongation
and potential drug–drug interactions with voriconazole.
Introduction
Invasive fungal infections in the intensive care unit (ICU) are often
missed or diagnosed late due to non-specific signs and symptoms, a low
index of suspicion, and the difficulty of differentiating between colo-
nization and infection [1]. However, invasive infections caused by fi-
lamentous fungi are potentially devastating.
Almost half of all cases of invasive aspergillosis (IA), the most fre-
quent invasive fungal infection [1], occur in the ICU [2]. Estimates of
the incidence of IA in critical care units range from 0.3% to 19% [3].
Patients with IA in the ICU are often referred with pre-existing infec-
tion, for example after developing respiratory failure in the bone
marrow transplant unit due to IA. Alternatively, patients who acquire
IA in the community or as a nosocomial infection may be admitted
directly to the ICU while, less often, patients may acquire IA while in
the ICU due to airborne spores in contaminated air. Reported mortality
rates following diagnosis of proven or probable IA are extremely high:
proven or probable IA in the ICU can lead to death in over 70–80% of
cases, largely due to delayed diagnosis [4].
In recent years, IA has become a major concern among non-neu-
tropenic patients with a mild degree of immunosuppression and
without classic predisposing risk factors [4]. The most common un-
derlying comorbidities in non-neutropenic patients are chronic ob-
structive pulmonary disease (COPD), acute respiratory distress syn-
drome, chronic corticosteroid therapy, liver cirrhosis, congenital or
acquired immunodeficiency, and recent thoracic or valvular surgery.
Prompt, appropriate antifungal therapy in IA is crucial to improve
clinical outcomes and reduce mortality. However, achieving a proven
diagnosis of IA in non-neutropenic patients is challenging, since clinical
manifestations (e.g. fever, cough and purulent sputum) are non-spe-
cific, and the conventional radiologic features of “halo sign” and “air
crescent sign” are present in only a minority of non-neutropenic pa-
tients.
Starting therapy at the stage of possible infection, as opposed to
proven or probable infection, might improve survival rates [5]. Vor-
iconazole is a first-line treatment for IA according to current guidelines
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[6] and is widely used. However, voriconazole has been associated with
an increased risk for adverse events, including renal impairment in
patients given intravenous therapy, hepatotoxicity, reversible ocular
disturbances, photosensitivity, exfoliative dermatitis, cutaneous reac-
tions, neurotoxicity and QT prolongation [7,8]. Moreover, since vor-
iconazole is metabolized by human P450 cytochromes, it has the po-
tential for drug–drug interactions in patients receiving other P450-
CYP3A4 substrates [9].
Isavuconazole is a novel triazole agent with a wide spectrum of
antifungal activity. It is recommended as a first-line therapy for IA in
recent guidelines from the European Conference on Infections in
Leukemia (ECIL) [10] and the Infectious Diseases Society of America
(IDSA) [11] based on the results of the phase III SECURE study which
demonstrated non-inferiority to voriconazole [12]. The main ad-
vantages of isavuconazole compared to voriconazole are: (1) reduced
nephrotoxicity in patients given intravenous therapy; (2) it does not
contribute to a prolonged QT interval; (3) fewer drug–drug interactions;
and (4) no requirement for dose adjustments in patients with renal or
hepatic impairment [12,13].
The following case report illustrates some potential issues in the
diagnostic work-up and management of patients admitted to the ICU
with probable invasive pulmonary aspergillosis (IPA).
Case report
Clinical presentation
A 69-year-old man with severe COPD requiring chronic oxygen
supplementation (1 L/min) and suspected underlying X-linked granu-
lomatous disease was admitted to the ICU with acute-on-chronic re-
spiratory failure. He had a progressively worsening cough, shortness of
breath, increased sputum production and had experienced a 10 kg
weight loss with muscle depletion in the preceding three months. The
patient had been treated for pulmonary tuberculosis at the age of 23
years, with no subsequent recurrence of infection. Chronic treatment
with clomipramine (75mg/day) was ongoing for a major depressive
syndrome which had been diagnosed five years earlier. He was being
monitored with monthly seriated electrocardiograms for QT prolonga-
tion attributable to clomipramine therapy.
Diagnosis of invasive pulmonary aspergillosis
At ICU admission, the patient presented with severe dyspnea.
Arterial blood-gas analysis showed mixed respiratory failure (pH 7.22,
PaO2 58mmHg, PaCO2 80mmHg, HCO3− 35mMol/L) requiring non-
invasive ventilation. Chest examination revealed bilateral crackles,
with no signs of chronic heart failure. Blood tests showed the white
blood cell count to be in the normal range (8000/mm3), with no neu-
tropenia (neutrophil count 1846/mm3), but mild lymphopenia was
present (lymphocytes 810/mm3). The patient was anemic (Hb 10.9 g/
dL). Platelet count was high (438,000/μL) and C-reactive protein (CRP)
was markedly increased (35mg/L; normal level< 5mg/L). Renal
function was normal (serum creatinine 0.9mg/dL), as were liver
function tests (aspartate transaminase [AST] 11 IU/L, alanine transa-
minase [ALT] 14 IU/L, gamma-glutamyl transpeptidase [GGT] 30 IU/L,
total bilirubin 0.15mg/dL). Baseline electrocardiogram showed a sinus
rhythm with a right bundle branch block and prolonged QT interval
(453ms).
Chest x-ray showed multiple bilateral lung opacities. CT and [18F]
fluorodeoxyglucose (FDG)-PET/CT scans revealed bilateral nodular in-
filtrates.
Due to the patient’s critical condition and the multiple potential
etiologies for the pulmonary infection, a bronchoscopy was performed,
which demonstrated purulent secretions. Broncho-alveolar lavage
(BAL) fluid was negative for bacteria, fungi, mycobacteria, Actinomyces
spp. and Nocardia, but tested positive for galactomannan (GM; ODI
2.6).
According to the European Organisation for Research and
Treatment of Cancer (EORTC) criteria for non-neutropenic patients [6],
the diagnosis of probable IPA was made based on the presence of
baseline predisposing comorbidities (severe COPD and suspected X-
linked granulomatous disease), the presence of bilateral nodular in-
filtrates, and GM positivity on BAL.
Treatment
Voriconazole was considered unsuitable due to the patient’s base-
line QT prolongation and the risk of a drug–drug interaction with clo-
mipramine, potentially leading to further QT prolongation and severe
cardiac arrhythmias. Isavuconazole therapy was selected, and started
with a loading dose of 200mg every 8 h for six doses, following by
200mg daily.
Outcome
After starting antifungal treatment with isavuconazole, the patient
showed a progressive improvement in his clinical condition. At week 2,
the arterial blood-gas analysis showed resolution of the decompensated
respiratory acidosis, with normalization of pH (pH 7.40, PaO2
62mmHg, PaCO2 50mmHg, HCO3− 30mMol/L). There was no further
need of non-invasive ventilation. On day 17, the patient was moved
from the ICU to the infectious diseases ward, and required only low
flow oxygen supplementation (1 L/min). He was discharged on day 42.
CT scanning and FDG-PET/TC after eight weeks of antifungal treatment
confirmed the improvement of pulmonary infiltrates. In total, a three-
month course of isavuconazole treatment was completed, and there
were no clinical or radiologic signs of infection after six months’ follow-
up. Isavuconazole was well-tolerated, with no adverse events and no
change in liver enzymes. Serial ECG monitoring showed no prolonga-
tion of the QT interval.
Discussion
Invasive fungal diseases have been categorized as proven, probable
or possible by the EORTC/MSG Consensus Group [6]. Proven diagnosis
of IA requires confirmation by histopathologic, cytopathologic, or di-
rect microscopic examination of a specimen obtained by needle as-
piration or biopsy [6], which inevitably involves a delay. Criteria for a
probable diagnosis in critically ill patients have been proposed [14]
that can help to expedite therapy. These require a lower respiratory
tract specimen culture positive for Aspergillus, compatible signs and
symptoms, abnormal medical images of the lungs by X-ray or CT scan,
with either host risk factors or a semi-quantitative Aspergillus-positive
culture of BAL fluid and detection of branching hyphae on cytological
smear [14]. GM positivity on BAL fluid, in particular, has high sensi-
tivity (87%) and specificity (87%) for the diagnosis of IA [15]. In our
patient, these criteria were met and the findings were also consistent
with probable IPA according to EORTC/MSG criteria [6].
Voriconazole is a standard first-line treatment for proven or prob-
able IA and is widely prescribed [6]. However, our patient was re-
ceiving the tricyclic antidepressant clomipramine which can increase
the QT interval (likely accounting for the prolonged QT interval in this
patient), and addition of voriconazole could compound this risk. A re-
cent retrospective study by Gueta et al. analyzed risk factors associated
with QT prolongation in a cohort of hemato-oncologic patients treated
with voriconazole [16]. Baseline QT prolongation (≥450ms) and low
serum potassium levels were found to be independent risk factors for a
prolonged QT interval [16]. Moreover, an increased risk has been ob-
served when voriconazole is administered in combination with other
drugs which can induce QT prolongation (e.g. fluoroquinolones and
methadone), potentially resulting in life-threatening arrhythmias such
as “torsade de pointes” [17,18]. Contrasting results were found in a
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post-hoc analysis of data from patients receiving isavuconazole in the
SECURE trial [12]. The analysis demonstrated that the 50% inhibitory
concentrations for L-type Ca2+ channels were higher than the max-
imum serum concentrations of non-protein-bound isavuconazole in
vivo. As a result, isavuconazole does not prolong the QT interval. In-
deed, isavuconazole is associated with a shortened QT interval, which
leads to its contraindication in patients with familial short QT syndrome
[13,19], a rare (100 reports in the literature to date) genetic disorder
characterized by accelerated repolarization and a predisposition for
cardiac arrest [20]. Here, another option might have been to change
clomipramine to an alternative agent with a lower risk for QT pro-
longation.
Voriconazole inhibits multiple enzymatic pathways and is a sub-
strate and inhibitor of multiple cytochromes including CYP2C19,
CYP2C9, CYP3A4 and CYP2B6 [21], increasing its potential for
drug–drug interactions with CYP inhibitors and inducers. Clomipra-
mine is metabolized by CYP2C19, and a possible interaction could not
be ruled out. The effect of different triazoles on the cytochrome P450
system varies; isavuconazole shows less extensive drug–drug interac-
tions than voriconazole and only interactions with CYP3A4 inducers or
inhibitors are of concern [19].
Mortality from IA in the critical care setting exceeds 70%, and this
patient had a particularly poor prognosis due to his comorbid COPD
and X-linked chronic granulomatous disease. Prompt initiation of an-
tifungal treatment was essential due to the patient’s critical condition,
but voriconzole was contraindicated due to the increased risk of QT
interval prolongation. The case described here shows that isavucona-
zole is effective and safe in the management of a critically ill non-
neutropenic patient with baseline QT prolongation and potential
drug–drug interactions with voriconazole.
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